A Sero-Epidemiologic Survey and Cost-effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients

Patients must be presenting for evaluation or treatment of a new cancer malignancy (including hematologic). Confirmed diagnosis (obtained from patient's medical record) must be within 120 days prior to the first clinic visit. Patients must be registered within 90 days after their first clinic visit. Patients presenting for �second opinions� of confirmed malignancies are eligible, including those who have started cancer treatment at other facilities; Patients are allowed to participate in other clinical trials; must be at least 18 years of age; Patients must have had their blood drawn for viral status testing for HIV, HBV and HCV prior to registration or provide acceptable viral status documentation prior to registration; acceptable viral status documentation includes viral test results for any of all of the viruses, dated within 365 days prior to registration, or viral load documentation for any or all of the viruses, dated within 365 days prior to registration. Note that patients providing acceptable viral status documentation must have blood drawn for testing prior to registration for any of the three viruses not covered by the documentation. Patients must sign and give written informed consent in accordance with institutional and federal guidelines; Blood specimens for banking for future research is optional for sites and patients. Patient consent must be obtained before specimen is collected. Individuals are ineligible if they have been diagnosed with a malignancy other than the current malignancy within the past five years, with the exception of basal cell or squamous cell skin cancer, in situ cervical cancer, or in situ breast cancer. Individuals are eligible if they have had no evidence of disease for a prior malignancy except as noted above, for at least five years prior to randomization.